Tsuboi K - Search Results

1

Detection of novel Fabry disease-associated pathogenic variants in Japanese patients by newborn and high-risk screening.

Sawada T, Kido J, Sugawara K, Matsumoto S, Takada F, Tsuboi K, Ohtake A, Endo F, Nakamura K. Sawada T, et al. Among authors: tsuboi k. Mol Genet Genomic Med. 2020 Nov;8(11):e1502. doi: 10.1002/mgg3.1502. Epub 2020 Oct 5. Mol Genet Genomic Med. 2020. PMID: 33016649 Free PMC article.

2

Prevalence of patients with lysosomal storage disorders and peroxisomal disorders: A nationwide survey in Japan.

Koto Y, Sakai N, Lee Y, Kakee N, Matsuda J, Tsuboi K, Shimozawa N, Okuyama T, Nakamura K, Narita A, Kobayashi H, Uehara R, Nakamura Y, Kato K, Eto Y. Koto Y, et al. Among authors: tsuboi k. Mol Genet Metab. 2021 Jul;133(3):277-288. doi: 10.1016/j.ymgme.2021.05.004. Epub 2021 May 12. Mol Genet Metab. 2021. PMID: 34090759

3

[Skin Lesion in Fabry Disease].

Tsuboi K, Kanzaki T. Tsuboi K, et al. Brain Nerve. 2019 Apr;71(4):354-359. doi: 10.11477/mf.1416201275. Brain Nerve. 2019. PMID: 30988220 Japanese.

4

Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α.

Tsuboi K, Yamamoto H. Tsuboi K, et al. Genet Med. 2014 Oct;16(10):766-72. doi: 10.1038/gim.2014.28. Epub 2014 Mar 20. Genet Med. 2014. PMID: 24651606 Free PMC article.

5

Correlations Between Serum Cholesterol and Vascular Lesions in Fabry Disease Patients.

Katsuta H, Tsuboi K, Yamamoto H, Goto H. Katsuta H, et al. Among authors: tsuboi k. Circ J. 2018 Nov 24;82(12):3058-3063. doi: 10.1253/circj.CJ-18-0378. Epub 2018 Oct 3. Circ J. 2018. PMID: 30282881 Free article. Clinical Trial.

6

Otological aspects of Fabry disease in patients with normal hearing.

Wang F, Yamamoto H, Yoshida T, Sugimoto S, Teranishi M, Tsuboi K, Sone M. Wang F, et al. Among authors: tsuboi k. Nagoya J Med Sci. 2019 Aug;81(3):469-475. doi: 10.18999/nagjms.81.3.469. Nagoya J Med Sci. 2019. PMID: 31579337 Free PMC article.

7

Enzyme replacement therapy in patients with Fabry's disease.

Tsuboi K. Tsuboi K. J Int Med Res. 2007 Jul-Aug;35(4):574-81. doi: 10.1177/147323000703500418. J Int Med Res. 2007. PMID: 17697536 Free article.

8

Descriptive epidemiology of Fabry disease among beneficiaries of the Specified Disease Treatment Research Program in Japan.

Tsuboi K, Suzuki S, Nagai M. Tsuboi K, et al. J Epidemiol. 2012;22(4):370-4. doi: 10.2188/jea.je20110101. Epub 2012 Jun 9. J Epidemiol. 2012. PMID: 22790789 Free PMC article.

9

Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.

Tsuboi K, Yamamoto H. Tsuboi K, et al. BMC Pharmacol Toxicol. 2017 Jun 7;18(1):43. doi: 10.1186/s40360-017-0152-7. BMC Pharmacol Toxicol. 2017. PMID: 28592315 Free PMC article.

10

Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson-Fabry disease.

Haga T, Okumura T, Isobe S, Somura F, Kano N, Kuwayama T, Yokoi T, Hiraiwa H, Kondo T, Sawamura A, Morimoto R, Yamamoto H, Tsuboi K, Murohara T. Haga T, et al. Among authors: tsuboi k. Ann Nucl Med. 2019 Dec;33(12):930-936. doi: 10.1007/s12149-019-01406-0. Epub 2019 Oct 11. Ann Nucl Med. 2019. PMID: 31605355

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

855 results

Search Page